Flu is the common term for influenza, a contagious viral respiratory illness affecting the nose, throat, and sometimes lungs. Illness severity ranges from mild to severe and can lead to hospitalization or death, especially in high-risk groups. Annual vaccination is a key preventive strategy.
The FDA approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults 50 and older. Full approval covers ages 50-64; accelerated approval covers 65+. Moderna expects availability later this year, pending CDC recommendation.
A WashU Medicine study found Moderna's investigational mRNA flu vaccine could reduce hospitalizations and deaths, offering longer protection than current shots. If FDA-approved, it would be the first mRNA flu vaccine, with a decision possible by early August.
FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine for adults 50+. It was 27% more effective than standard flu shots in a large trial. The approval came after earlier FDA pushback.
Moderna posted a narrower-than-expected Q2 loss, with mFLUSIVA awaiting an FDA decision and a Phase 3 norovirus trial missing early success criteria. It reaffirmed 2026 revenue growth and cash guidance.
FDA's advisory committee voted 9-0 that Moderna's mRNA flu vaccine mFlusiva benefits outweigh risks for adults 50-64 and 65+, clearing a key hurdle before an Aug. 5, 2026 decision. The FDA initially declined to review the BLA before reversing course.
The Bundibugyo Ebola outbreak in the DRC has surpassed 3,200 cases and 1,400 deaths, becoming the fastest-spreading Ebola outbreak ever. The first-ever Bundibugyo-specific vaccine trial has begun at Oxford, while healthcare workers at the epicenter have gone on strike over unpaid wages. The WHO has declared the outbreak a global health emergency.
New imaging reveals that most flu infections fail due to transcription errors, while host-targeted antivirals aim to bypass resistance by interfering with cellular machinery. The findings from Cell Systems point to new ways to predict viral threats and develop broad-spectrum drugs.
Measles cases in the U.S. reached 2,288 in 2025, the highest since 1992, with 2,104 cases reported in the first half of 2026. Utah has seen 499 cases this year, more than 20% of the national total, driven by pockets of low vaccination. Health officials emphasize vaccination and early symptom recognition to prevent spread.
The FDA reversed its initial rejection of Moderna's mRNA flu vaccine, agreeing to a normal review after public backlash, while a federal judge invalidated the ACIP advisory committee, leaving the US without functioning vaccine oversight. Moderna's vaccine showed 26.6% greater efficacy than standard flu shots in clinical trials.
FDA's vaccine advisory committee unanimously recommended Moderna's mRNA flu vaccine mFlusiva for adults 50 and over, the committee's first new vaccine review since 2023. The FDA expects an approval decision by Aug 5, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07147517 |
Preparedness Through Respiratory Virus Epidemiology and Community Engagement |
RECRUITING | |
| NCT07007377 |
Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients |
COMPLETED | |
| NCT06626321 |
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication |
COMPLETED | NA |
| NCT06385821 |
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus |
COMPLETED | PHASE3 |
| NCT06158659 |
Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula |
COMPLETED | NA |
| NCT06057727 |
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges |
COMPLETED | NA |
| NCT05473325 |
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) |
UNKNOWN | |
| NCT05435144 |
Elderberry for Immune Support |
UNKNOWN | NA |
| NCT05417997 |
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients |
COMPLETED | PHASE3 |
| NCT04515446 |
Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza |
ACTIVE_NOT_RECRUITING | NA |
